By Lina Amrani, Nurin Sabrina Zawari, Nur Zahirah Afrina Abd Rahman, Adzzie Shazleen Azman, Nurshamimi Nor Rashid, Jasmine Elanie Khairat
{"title":"解开大自然隐藏的宝藏:放线菌的有效抗病毒化合物库对抗人类病毒感染。","authors":"By Lina Amrani, Nurin Sabrina Zawari, Nur Zahirah Afrina Abd Rahman, Adzzie Shazleen Azman, Nurshamimi Nor Rashid, Jasmine Elanie Khairat","doi":"10.1016/j.micpath.2025.107953","DOIUrl":null,"url":null,"abstract":"<p><p>The global emergence of infectious diseases, including COVID-19, Mpox, MERS, Ebola, dengue, Zika, and avian influenza, alongside the escalation of antimicrobial resistance, has made the discovery of novel antiviral agents an urgent priority. Actinomycetota, a diverse group of microorganisms known for their medicinal properties and antibiotic production, stand out as a promising source of antiviral compounds. Since the 20th century, studies on the antiviral potential of Actinomycetota-derived secondary metabolites have shown efficacy against various human viruses, such as influenza viruses (IVs), human coronaviruses (hCoVs), respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), mosquito-borne viruses such as Zika virusZIKV), dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)), and monkeypox virus (MPXV). This review provides a comprehensive summary of key findings from the literature, emphasizing the theurapeutic potential of these compounds and the importance of further research to elucidate their mechanisms of action and enhance their production. Unlocking the antiviral arsenal of Actinomycetota may pave the way for the development of novel and effective antiviral therapies to combat human viral diseases.</p>","PeriodicalId":18599,"journal":{"name":"Microbial pathogenesis","volume":" ","pages":"107953"},"PeriodicalIF":3.5000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking nature's hidden treasures: Actinomycetota's arsenal of potent antiviral compounds against human viral infections.\",\"authors\":\"By Lina Amrani, Nurin Sabrina Zawari, Nur Zahirah Afrina Abd Rahman, Adzzie Shazleen Azman, Nurshamimi Nor Rashid, Jasmine Elanie Khairat\",\"doi\":\"10.1016/j.micpath.2025.107953\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The global emergence of infectious diseases, including COVID-19, Mpox, MERS, Ebola, dengue, Zika, and avian influenza, alongside the escalation of antimicrobial resistance, has made the discovery of novel antiviral agents an urgent priority. Actinomycetota, a diverse group of microorganisms known for their medicinal properties and antibiotic production, stand out as a promising source of antiviral compounds. Since the 20th century, studies on the antiviral potential of Actinomycetota-derived secondary metabolites have shown efficacy against various human viruses, such as influenza viruses (IVs), human coronaviruses (hCoVs), respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), mosquito-borne viruses such as Zika virusZIKV), dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)), and monkeypox virus (MPXV). This review provides a comprehensive summary of key findings from the literature, emphasizing the theurapeutic potential of these compounds and the importance of further research to elucidate their mechanisms of action and enhance their production. Unlocking the antiviral arsenal of Actinomycetota may pave the way for the development of novel and effective antiviral therapies to combat human viral diseases.</p>\",\"PeriodicalId\":18599,\"journal\":{\"name\":\"Microbial pathogenesis\",\"volume\":\" \",\"pages\":\"107953\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbial pathogenesis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.micpath.2025.107953\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial pathogenesis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.micpath.2025.107953","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Unlocking nature's hidden treasures: Actinomycetota's arsenal of potent antiviral compounds against human viral infections.
The global emergence of infectious diseases, including COVID-19, Mpox, MERS, Ebola, dengue, Zika, and avian influenza, alongside the escalation of antimicrobial resistance, has made the discovery of novel antiviral agents an urgent priority. Actinomycetota, a diverse group of microorganisms known for their medicinal properties and antibiotic production, stand out as a promising source of antiviral compounds. Since the 20th century, studies on the antiviral potential of Actinomycetota-derived secondary metabolites have shown efficacy against various human viruses, such as influenza viruses (IVs), human coronaviruses (hCoVs), respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), mosquito-borne viruses such as Zika virusZIKV), dengue virus (DENV), West Nile virus (WNV), Chikungunya virus (CHIKV)), and monkeypox virus (MPXV). This review provides a comprehensive summary of key findings from the literature, emphasizing the theurapeutic potential of these compounds and the importance of further research to elucidate their mechanisms of action and enhance their production. Unlocking the antiviral arsenal of Actinomycetota may pave the way for the development of novel and effective antiviral therapies to combat human viral diseases.
期刊介绍:
Microbial Pathogenesis publishes original contributions and reviews about the molecular and cellular mechanisms of infectious diseases. It covers microbiology, host-pathogen interaction and immunology related to infectious agents, including bacteria, fungi, viruses and protozoa. It also accepts papers in the field of clinical microbiology, with the exception of case reports.
Research Areas Include:
-Pathogenesis
-Virulence factors
-Host susceptibility or resistance
-Immune mechanisms
-Identification, cloning and sequencing of relevant genes
-Genetic studies
-Viruses, prokaryotic organisms and protozoa
-Microbiota
-Systems biology related to infectious diseases
-Targets for vaccine design (pre-clinical studies)